Status:
COMPLETED
Transcranial Direct Current Stimulation to Modulate Top-Down Regulation for Drug Craving in Methamphetamine Use Disorder
Lead Sponsor:
Laureate Institute for Brain Research, Inc.
Conditions:
Amphetamine Use Disorders
Eligibility:
MALE
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
Methamphetamine use disorder (MUD) is among the costliest and deadliest substance use disorders (SUDs) world-wide and is frequently comorbid with other mental health conditions. There is no empiricall...
Detailed Description
Methamphetamine use disorder (MUD) is among the costliest and deadliest substance use disorders (SUDs) world-wide and is frequently comorbid with other mental health conditions. There is no empiricall...
Eligibility Criteria
Inclusion
- English speaking.
- Diagnosed with Methamphetamine Use Disorder (last 12 months) based on the Mini International Neuropsychiatric Interview (MINI) interview (Diagnostic and Statistical Manual of Mental Disorders-DSM-5)
- Being abstinent from methamphetamine in an addiction treatment program for at least one week based on medical records or self-report
- Positive response to Methamphetamine cue-reactivity screening (MCS)
- Willing and capable of interacting with the informed consent process
Exclusion
- Unwillingness or inability to complete any of the major aspects of the study protocol, including magnetic resonance imaging (i.e., due to claustrophobia), drug cue rating, or behavioral assessment.
- Abstinence from methamphetamine for more than 6 months based on self-report
- Schizophrenia or bipolar disorder based on the MINI interview
- Active suicidal ideation with intent or plan determined by self-report or assessment by PI or study staff during the initial screening or any other phase of the study
- Positive drug test for amphetamines, opioids, cannabis, alcohol,Phencyclidine (PCP), or cocaine confirmed by breath analyzer and urine tests
- Any active skin disorder that affects skin integrity of the scalp
- Having any condition that would preclude undergoing an fMRI scan or tDCS stimulation based on the fMRI safety and tDCS safety checklists
- Unstable medical disorder reported in subject's medical history or by a clinician assessment
- History of seizure
- Non-correctable vision or hearing problems.
- Any other condition the PI or study staff feel would put the subject at risk for entering the study
Key Trial Info
Start Date :
November 30 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 10 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03382379
Start Date
November 30 2017
End Date
February 10 2019
Last Update
June 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laureate Institute for Brain Research
Tulsa, Oklahoma, United States, 74136